ÄϹ¬¼¯ÍÅ

STEM CELLS£º¼ä³äÖʸÉϸ°ûÖÎÁƹÚÐIJ¡Çå¾²ÓÐÓ㬣¬£¬£¬£¬£¬Ó¦ÓÃÔ¶¾°ÁÉÀ«

¹ÚÐIJ¡£¬£¬£¬£¬£¬£¬È«³Æ¹Ú×´¶¯ÂöÖàÑùÓ²»¯ÐÔÐÄÔಡ£¡£¬£¬£¬£¬£¬£¬ÊǹÚ×´¶¯ÂöѪ¹Ü±¬·¢¶¯ÂöÖàÑùÓ²»¯²¡±ä¶øÒýÆðѪ¹ÜÇ»ÏÁÕ­»òÛÕ±Õ£¬£¬£¬£¬£¬£¬Ôì¹ÊÒ⼡ȱѪ¡¢È±Ñõ»ò»µËÀ¶øµ¼ÖµÄÐÄÔಡ¡£¡£

΢ÐŽØÍ¼_20210825094944.png


ÌìÏÂÎÀÉú×éÖ¯(WHO)Ðû²¼Êý¾Ýͳ¼Æ£¬£¬£¬£¬£¬£¬×Ô2000µ½2020µÄ20Äêʱ¼äÀ£¬£¬£¬£¬£¬¹ÚÐIJ¡Î»ÁÐÈ«ÈËÀàÖÂËÀÔµ¹ÊÔ­ÓɵÚһλ, Õ¼ÌìÏÂ×ÜéæÃüÈËÊýµÄ16%£¬£¬£¬£¬£¬£¬ÊÇÍþвÈËÀ࿵½¡µÄ¡°Í·ºÅɱÊÖ¡±£¬£¬£¬£¬£¬£¬²¢ÇÒ»¼²¡ÈËÊý·ºÆðÏÔ×ŵÄÔöÌíÇ÷ÊÆ£¬£¬£¬£¬£¬£¬20ÄêÔöÌíÁË200¶àÍòÈË¡£¡£




¼ä³äÖʸÉϸ°ûÖÎÁƹÚÐIJ¡£¡£º

20ÄêÑо¿Àú³Ì



¶Ô´ó²¿·ÖÍíÆÚ¹ÚÐIJ¡»¼ÕßÀ´Ëµ£¬£¬£¬£¬£¬£¬ÐÄÔàÒÆÖ²ÊÇÆäΨһѡÔñ£¬£¬£¬£¬£¬£¬µ«¹©Ìåȱ·¦¡¢ºã¾ÃʹÓÃÃâÒßÒÖÖÆ¼ÁµÄ²»Á¼·´Ó¦¡¢Ô¤ºóµÄ²»È·¶¨ÐÔÒÔ¼°Óöȸ߰ºµÈÔµ¹ÊÔ­ÓÉÑÏÖØÓ°Ï컼ÕßµÄÉúÑÄÖÊÁ¿ºÍÉúÑÄÂÊ¡£¡£


Ëæ×Åϸ°ûÁÆ·¨µÄÊÖÒÕÒ»Ö±Éú³¤£¬£¬£¬£¬£¬£¬¸Éϸ°ûÁÆ·¨Îª¹ÚÐIJ¡ÌṩÁËеÄ˼Ð÷¡£¡£


¼ä³äÖʸÉϸ°ûÃâÒßÔ´ÐԵͣ¬£¬£¬£¬£¬£¬ÔÚÌåÍâ×÷ÓýÈÝÒ×´ó×ÚÀ©ÔöÇÒÈÔÈ»±£´æ¡°¸Éϸ°û¡±ÌØÕ÷£¬£¬£¬£¬£¬£¬ÊÇÐÞ¸´ËðÉËÐÄ×î¼Ñºòѡϸ°û¡£¡£

΢ÐŽØÍ¼_20210825165229.png

¹ØÓÚ¼ä³äÖʸÉϸ°û´Ì¼¤ÐÄÔàÔÙÉúÄÜÁ¦ÒѾ­Ñо¿ÁË20Ä꣬£¬£¬£¬£¬£¬¶àÏîÁÙ´²Ç°Êý¾ÝºÍÁÙ´²Ñо¿Ð§¹ûÅú×¢¼ä³äÖʸÉϸ°ûÖÎÁƹÚÐIJ¡ÓÐןÜÊÇÓÅÒìµÄÓ¦ÓÃÔ¶¾°¡£¡£

΢ÐŽØÍ¼_20210825112052.png






¼ä³äÖʸÉϸ°û(MSCs)ÖÎÁƹÚÐIJ¡µÄ»úÖÆ


1.MSCs´Ì¼¤ÐÄÔàϸ°ûµÄÔöÖ³ºÍ·Ö½â¡£¡£

2.MSCsÉøÍ¸Éú³¤Òò×ÓÔö½øÐÄÔàÐÞ¸´¡£¡£

3.MSCsÍâÃÚÌåïÔÌ­Ðļ¡Ï¸°ûµòÍö¡£¡£

΢ÐŽØÍ¼_20210825165343.png




ÁÙ´²Ñо¿Ö¤ÊµÇå¾²ÐÔºÍÓÐÓÃÐÔ


×Ô2011ÄêÒÔÀ´£¬£¬£¬£¬£¬£¬¿ªÕ¹Á˶àÏî¹ØÓÚ¼ä³äÖʸÉϸ°ûÖÎÁƹÚÐIJ¡µÄÁÙ´²Ñо¿£¬£¬£¬£¬£¬£¬²¢È¡µÃÁËһЩÆð¾¢ÓÐÓõÄЧ¹û¡£¡£


Êý¾ÝÅú×¢£º¼ä³äÖʸÉϸ°ûÖÎÁƹÚÐIJ¡¾ßÓкܸߵÄÇå¾²ÐÔ¡£¡£


ÔÚÒ»Ïî°üÀ¨ÓÐÇá¶È¡¢ÖжÈÖÁÖØ¶ÈÐĽÊÍ´µÄ31Ãû»¼ÕßʵÑéÖУ¬£¬£¬£¬£¬£¬¼ä³äÖʸÉϸ°ûͨ¹ýÐļ¡ÄÚ×¢ÉäµÝËÍÖÁÌåÄÚ£¬£¬£¬£¬£¬£¬ËùÓÐʵÑéÕß½ÓÊÜ6¸öÔµÄËæ·Ã£¬£¬£¬£¬£¬£¬Ê±´úûÓзºÆðÓëϸ°ûʵÑéÏà¹ØµÄÊÒÐÔÐÄÂÉʧ³£» £»£»òÆäËûÖ÷Òª²»Á¼ÐÄÔàÊÂÎñ¡£¡£


¼ä³äÖʸÉϸ°ûÖÎÁƺ󣬣¬£¬£¬£¬£¬ÄÜÏÔןÄÉÆÐÄÔ๦Ч£¬£¬£¬£¬£¬£¬ïÔÌ­Ð£ËÀÃæ»ý£¬£¬£¬£¬£¬£¬ÏÔ׎µµÍÐ£ËÀ¸´·¢ÂʺÍéæÃüÂÊ¡£¡£


×èÖ¹2021Äê6Ô£¬£¬£¬£¬£¬£¬ÔÚÃÀ¹ú¹úÁ¢ÎÀÉúÑо¿ÔºµÄÁÙ´²ÊÔÑé×¢²áÍøÕ¾(clinicaltrials.gov)ÉÏÓйؼä³äÖʸÉϸ°ûÖÎÁƹÚÐIJ¡ÁÙ´²ÏîÄ¿µÖ´ï56Ïî¡£¡£½ü¼¸ÄêÀ´·ºÆðÒ»Ö±Ôö¶àµÄÇ÷ÊÆ£¬£¬£¬£¬£¬£¬ÏÔʾ³öÖØ´óµÄÓ¦ÓÃDZÁ¦ºÍÔ¶¾°¡£¡£

΢ÐŽØÍ¼_20210825165207.png

±¸×¢£º±í¸ñÄÚÈÝÕûÀí×ÔStem Cell Translational Medicine£¬£¬£¬£¬£¬£¬ÏêϸÏîÄ¿ÐÅÏ¢¿ÉÒÔʹÓñàºÅÔÚclinicaltrials.govÍøÕ¾ÉÏÅÌÎÊ




½áÓï



²î±ðµÄÑо¿Ð§¹ûÅú×¢»¼ÕߵĸöÌå²î±ð¡¢²î±ðµÄϸ°û×÷Óý·½·¨¡¢ÒÆÖ²·½·¨ºÍ¼ÁÁ¿¡¢ÊÔÑéÊÓ²ìÊý¾Ý»ù×¼Ïß²î±ðµÈÒòËØ¿ÉÄܶ¼»áÓ°Ïìµ½Ñо¿Ð§¹û£¬£¬£¬£¬£¬£¬ºóÃæ½×¶ÎµÄÁÙ´²Ñо¿ÐèÒª¸ü¶àϵͳÐԵıÈÕպͺã¾ÃËæ·ÃЧ¹û¡£¡£×ÛÉÏËùÊö£¬£¬£¬£¬£¬£¬¼ä³äÖʸÉϸ°ûÖÎÁƹÚÐIJ¡µÄÇå¾²ÐԺͿÉÐÐÐÔ¶¼ÒѾ­»ñµÃ֤ʵ£¬£¬£¬£¬£¬£¬Ô¶¾°ÁÉÀ«¡£¡£

²Î¿¼ÎÄÏ×
1¡¢STEM CELLS TranslationaMedicine. Volume 9, Issue 10. p. 1121-1128.
2¡¢Ward MR, Abadeh A, Connelly KA. Concise Review: Rational Use of Mesenchymal Stem Cells in the Treatment of Ischemic Heart Disease. Stem Cells Transl Med. 2018 Jul;7(7):543-550.
3¡¢Leiker M, Suzuki G, Iyer VS et al. Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells. Cell Transplant 2008;17:911¨C922.
4¡¢Takahashi M, Li TS, Suzuki R et al. Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol 2006;291:H886¨CH893.
5¡¢Feng Y, Huang W, Wani M et al. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS One 2014;9:e88685.
6¡¢Friis T, Haack-S?rensen M, Mathiasen AB et al. Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scand Cardiovasc J 2011;45:161¨C168.


END



ÏëÒª×Éѯ¹ÚÐIJ¡ÖÎÁÆ¿µ¸´/ÐÄѪ¹Ü¼²²¡ÖÎÁÆ¿µ¸´/Éñ¾­ÍËÐÐÐÔ¼²²¡É¸²éÓëÖÎÁÆ/Ç¿Ì忹˥/ÑÇ¿µ½¡¸ÄÉÆ/ÌáÉýÃâÒßÁ¦£¿£¿£¿£¿£¿»òÕßÊÇÆäËû¸ü¶àµÄ¿µ½¡ÖÎÀíЧÀÍ×ÊѶ£¿£¿£¿£¿£¿


Çë¹Ø×¢Î¢ÐÅС³ÌÐò¡ª¡ªÄϹ¬¼¯ÍÅϸ°û×ÊѶ£¬£¬£¬£¬£¬£¬ÌåÑé˽ÈËÒ½Éú¿µ½¡Ð§ÀÍ¡£¡£

Çë¹Ø×¢Î¢ÐŹ«Öںšª¡ªÄϹ¬¼¯ÍÅϸ°ûequalcell£¬£¬£¬£¬£¬£¬Ïàʶ¸ü¶à¿µ½¡×ÊѶ¡£¡£


¡¾ÍøÕ¾µØÍ¼¡¿